Navigation Links
Chronic Exposure To Benzene May Result In Dysplasia

Autoimmune-mediated bone marrow injury is an early or predisposing event in the pathogenesis of benzene-induced persistent hematopoietic disease, according to recent // research which appears online on September 23 in the journal Leukemia Research.

Myelodysplastic syndrome is a heterogeneous group of diseases characterized by ineffective hematopoiesis, dysplasia in one or more hematopoietic lineages, clonal evolution and a tendency to progress on to bone marrow failure or acute myelogenous leukemia.

Hematotoxicity following chronic benzene exposure has been recognized for over a century, although the mechanism remains unknown.

This paper describes a novel form of bone marrow dysplasia in 23 workers exposed to high concentrations of benzene.

Distinguishing features of benzene-induced dysplasia include: marked dyserythropoiesis, eosinophilic dysplasia and abnormal cytoplasmic granulation of neutrophilic precursors.

Hematophagocytosis, stromal degeneration and bone marrow hypoplasia were also seen. Severe bone marrow dysplasia was found to be frequently accompanied by clonal T cell expansion and alterations in T lymphocyte subsets. No clonal cytogenetic abnormalities were observed. .

The authors conclude that these observations indicate that previous chronic exposure to benzene is associated with the development of BM dysplasia, and suggest that a reactive inflammatory process may be involved in the suppression of hematopoiesis in persistent BM failure following chronic benzene exposure. These findings further suggest the possibility that markers of immune activation or inflammation may prove useful in monitoring the development or progression of benzene-induced dysplastic disease.
'"/>




Page: 1

Related medicine news :

1. Roller coasters – cause “Chronic Headache?
2. In Chronic Diseases - Poor compliance of Patients with drug treatment
3. New Treatment for Chronic Eczema
4. Novel Therapy for Chronic Problem
5. Overcoming Chronic Fatigue
6. Chronic Fatigue, Pain Linked to Sinusitis
7. Chronic Diseases said to Cause Falls in the Elderly
8. Epilepsy Drug May Relieve Chronic Headaches
9. Women Worse Affected By Chronic Cough
10. A Drug That Might Relieve Chronic Cough
11. A Sedentary Childhood Could Lead To Chronic Fatigue Latter In Life
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/20/2017)... ... June 20, 2017 , ... AMC Health , the leading provider ... the clinical trials market. Similar to its approach in demonstrating positive outcomes in the ... marketplace by proving the value of eVisits to support virtual studies. , ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... in Cincinnati, OH for leading-edge care, whether or not they have a referral. ... the BIOLASE WaterLase® iPlus™ laser, she targets bacteria and damaged tissue without affecting ...
(Date:6/20/2017)... JEFFERSON HILLS, PA (PRWEB) , ... June 20, ... ... now available at Allegheny Health Network’s (AHN) Jefferson Hospital is providing physicians with ... 1.5T, 48-channel scanner provides higher-resolution images than traditional MRIs, enabling doctors to get ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... SweetLeaf® Stevia Sweetener, Michael P. May, Ph.D., recently accepted the distinguished Sun Corridor ... Program selected Wisdom Natural Brands (WNB), and 16 other businesses from Pima, Pinal, ...
(Date:6/20/2017)... ... 20, 2017 , ... BrightStar Care Centerville/South Dayton, a home ... Joint Commission, which accredits and certifies nearly 21,000 healthcare organizations and programs in ... symbol of quality that reflects an organization’s commitment to meeting certain performance standards. ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
(Date:5/30/2017)... May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... Global Healthcare Conference on Tuesday, June 13, 2017, in ... , Hill-Rom,s president and chief executive officer, is scheduled to ... audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . A ... the live event through September 13, 2017. ...
Breaking Medicine Technology: